Clinical trials: Albright Hereditary Osteodystrophy
Pseudohypoparathyroidism Type 1A, Albright Hereditary Osteodystrophy
Energy Expenditure and Body Composition in Pseudohypoparathyroidism 1a
The investigators would like to learn more about the metabolic consequences of pseudohypoparathyroidism type 1a in children, adolescents and adults with this condition.
- Trial name
- NCT01398774
- Where
- United States
- Volunteers
- 519 people, healthy volunteers welcome
- Sponsor
- Children's Hospital of Philadelphia
Pseudohypoparathyroidism, Pseudohypoparathyroidism Type 1a
Theophylline for Treatment of Pseudohypoparathyroidism
Pseudohypoparathyroidism is a genetic disorder with limited treatment options, characterized by early-onset obesity, short stature, hormone resistance and cognitive impairment.
- Conditions
- Pseudohypoparathyroidism, Pseudohypoparathyroidism Type 1a, Albright Hereditary Osteodystrophy
- Trial name
- NCT04240821
- Testing
- Theophylline ER
- Where
- United States
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Jaclyn Tamaroff
Pseudohypoparathyroidism, Albright Hereditary Osteodystrophy
Early-onset Obesity and Cognitive Impairment in Children With Pseudohypoparathyroidism
Pseudohypoparathyroidism type 1a (PHP1a) is a rare disease that causes childhood obesity and learning difficulties. This study will investigate eating behaviors and perform cognitive testing on children with PHP1a.
- Trial name
- NCT02411461
- Where
- United States
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- Vanderbilt University Medical Center